Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Formation Biologics
Numab Therapeutics AG
NextCure, Inc.
Eisai Inc.
Genmab
OncoNano Medicine, Inc.
Nektar Therapeutics
Herlev Hospital
Calithera Biosciences, Inc
Ludwig Institute for Cancer Research
Incyte Corporation
Eli Lilly and Company
Incyte Corporation
Institut Bergonié
Millennium Pharmaceuticals, Inc.
INSYS Therapeutics Inc
East and North Hertfordshire NHS Trust